Perimeter Partners with Intermountain Health to Study the Potential Clinical, Social and Economic Benefits of Using OCT and AI to Reduce Cancer Reoperations

Intermountain Health will support a retrospective analysis of reoperation rates and healthcare costs associated with breast-conserving surgery using Perimeter Medical Imaging AI's technology. The study aims to evaluate the potential of Perimeter's wide-field OCT interoperative margin assessment technology to improve surgical oncology outcomes and care delivery efficiency, with a focus on the total cost of cancer reoperations for both patients and payers.

Analysis

Intermountain Health is set to support a retrospective analysis focusing on reoperation rates and the associated incremental healthcare costs for patients undergoing breast-conserving surgery, leveraging Perimeter Medical Imaging AI's proprietary wide-field OCT interoperative margin assessment technology. This collaboration aims to evaluate the technology's potential to optimize surgical oncology outcomes and enhance the efficiency of care delivery. A key aspect of the study will be Intermountain Health's unique capability, due to its integrated healthcare system and own health plan, to assess the total cost impact of cancer reoperations on both patients and payers. While the announcement carries a 'strongly positive' sentiment and 'moderate' market impact score, indicating optimistic potential, the information is characterized by forward-looking statements regarding the anticipated benefits of Perimeter's S-Series OCT, B-Series OCT, and ImgAssist AI. These statements are inherently subject to significant medical, scientific, and business uncertainties, including the need for positive trial results and regulatory approvals, as explicitly detailed in the provided disclaimers. The study represents an effort to generate data supporting the clinical and economic value proposition of Perimeter's technology within the themes of AI, technology innovation, and healthcare.

Key Decisions for Investors

• Investors should view this collaboration as a positive step for Perimeter Medical Imaging AI, as a successful retrospective analysis with Intermountain Health could provide crucial data on the economic and clinical benefits of its OCT technology, potentially de-risking future adoption.
• Monitor the outcomes of this retrospective analysis closely; quantifiable evidence of reduced reoperation rates and cost savings would serve as a significant catalyst for Perimeter's technology and its valuation.
• Given the reliance on forward-looking statements and the inherent risks in medical technology development, particularly for companies potentially in earlier commercial stages, maintain a cautious outlook, focusing on the achievement of stated research outcomes, subsequent clinical trial results, and regulatory milestones before making significant investment decisions.